[1] Lazzari L, Lucchi S, Rebulla P, et al. Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin(IL)-6 and IL-11 in a serum-free and stroma-free culture system[J].Hema-tology, 2001, 112:397-404.
[2] Taguchi K, Saitoh M, Arai Y, et al. Disparate effects of interleukin 11 and thrombopoietin on megakaryocytopoiesis in vitro[J]. Cytokine, 2001,5:241-249.
[3] Weich NS, Fitzgerald M, Wang A, et al. Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro[J]. Blood, 2000, 95:503-509.
[4] Cairo MS, Plunkett JM, Nguyen A, et al. Effect of interleukin-11 with and without granulocyte colony-stimulating factor on in vivo neonatal rat hematopoiesis:induction of neonatal thrombocytosis by interleukin-11 and synergistic enhancement of neutrophilia by interleukin-11+granulocyte colony-stimulating factor[J]. Pediatr Res, 1993, 34:56-61.
[5] Nash RA, Seidel K, Storb R, et al. Effects of rhIL-11 on normal dogs and after sublethal radiation[J]. Exp Hematol,1995, 23:389-396.
[6] Schlerman FJ, Bree AG, Kaviani MD, et al. Thrombopoietic activity of recombinant human interleukin 11(rHuIL-11) in normal and myelosuppressed nonhuman primates[J]. Stem Cells, 1996,14:517-532.
[7] Saitoh M, Taguchi K, Momose K, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocy-topenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells[J]. Cancer Chemother Pharmacol, 2002, 49:161-166.
[8] Saitoh M, Taguchi K, Momose K, et al. Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11 in myelosuppressed mice[J]. Cytokine, 2001, 13:287-294.
[9] Van der Meeren A, Mouthon MA, Gaugler MH, et al. Administration of recombinant human IL-11 after supralethal radiation exposure promotes survival in mice:interactive effect with thrombopoietin[J]. Radiat Res, 2002, 157:642-649.
[10] Reynolds CH. Clinical efficacy of rhIL-11[J]. Oncology (Huntingt), 2000, 14(Suppl 8):32-40.
[11] Issacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin[J]. J Clin Oncol, 1997, 15:3368-3377.
[12] Feinglass S, Deodhar A. Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11[J]. Arthritis Rheum, 2001, 44:170-175.
[13] Goldman SC, Bracho F, Davenport V, et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients[J]. Pediatr Hematol Oncol, 2001, 23:300-305.
[14] Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP[J]. Hematol, 2001, 66:172-177.
[15] Smith JW 2nd. Tolerability and side-effect profile of rhIL-11[J]. Oncology(Huntingt), 2000, 14(Suppl 8):41-47.